Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Perioperative cancer cell dissemination detected with a real-time RT-PCR assay for EpCAM is not associated with worse prognosis in pancreatic ductal adenocarcinoma.

Sergeant G, Roskams T, van Pelt J, Houtmeyers F, Aerts R, Topal B.

BMC Cancer. 2011 Jan 31;11:47. doi: 10.1186/1471-2407-11-47.

2.
3.

Pancreatic cancer circulating tumour cells express a cell motility gene signature that predicts survival after surgery.

Sergeant G, van Eijsden R, Roskams T, Van Duppen V, Topal B.

BMC Cancer. 2012 Nov 16;12:527. doi: 10.1186/1471-2407-12-527.

4.

Serum EpCAM expression in pancreatic cancer.

Gebauer F, Struck L, Tachezy M, Vashist Y, Wicklein D, Schumacher U, Izbicki JR, Bockhorn M.

Anticancer Res. 2014 Sep;34(9):4741-6.

PMID:
25202052
5.

Detection of micrometastatic breast cancer by means of real time quantitative RT-PCR and immunostaining in perioperative blood samples and sentinel nodes.

Schröder CP, Ruiters MH, de Jong S, Tiebosch AT, Wesseling J, Veenstra R, de Vries J, Hoekstra HJ, de Leij LF, de Vries EG.

Int J Cancer. 2003 Sep 10;106(4):611-8.

6.

Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients.

Zhao S, Yang H, Zhang M, Zhang D, Liu Y, Liu Y, Song Y, Zhang X, Li H, Ma W, Zhang Q.

Cell Biochem Biophys. 2013 Mar;65(2):263-73. doi: 10.1007/s12013-012-9426-2.

PMID:
22990361
7.

Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients.

Obermayr E, Sanchez-Cabo F, Tea MK, Singer CF, Krainer M, Fischer MB, Sehouli J, Reinthaller A, Horvat R, Heinze G, Tong D, Zeillinger R.

BMC Cancer. 2010 Dec 3;10:666. doi: 10.1186/1471-2407-10-666.

8.

Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study.

de Albuquerque A, Kubisch I, Breier G, Stamminger G, Fersis N, Eichler A, Kaul S, Stölzel U.

Oncology. 2012;82(1):3-10. doi: 10.1159/000335479.

PMID:
22270149
9.

Presence of minute cancer cell dissemination in peritoneal lavage fluid detected by reverse transcription PCR is an independent prognostic factor in patients with resectable pancreatic cancer.

Eguchi H, Ohigashi H, Takahashi H, Yano M, Motoori M, Miyashiro I, Kishi K, Ohue M, Noura S, Seki Y, Yamada T, Goto K, Yamamoto T, Idota A, Fujii J, Nakajima H, Yamasaki T, Ishikawa O.

Surgery. 2009 Nov;146(5):888-95. doi: 10.1016/j.surg.2009.04.021.

PMID:
19744431
10.
11.

Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration.

Chen Y, Zheng B, Robbins DH, Lewin DN, Mikhitarian K, Graham A, Rumpp L, Glenn T, Gillanders WE, Cole DJ, Lu X, Hoffman BJ, Mitas M.

Int J Cancer. 2007 Apr 1;120(7):1511-7.

12.

Histological and prognostic importance of CD44(+) /CD24(+) /EpCAM(+) expression in clinical pancreatic cancer.

Ohara Y, Oda T, Sugano M, Hashimoto S, Enomoto T, Yamada K, Akashi Y, Miyamoto R, Kobayashi A, Fukunaga K, Morishita Y, Ohkohchi N.

Cancer Sci. 2013 Aug;104(8):1127-34. doi: 10.1111/cas.12198.

13.

Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.

Onstenk W, Kraan J, Mostert B, Timmermans MM, Charehbili A, Smit VT, Kroep JR, Nortier JW, van de Ven S, Heijns JB, Kessels LW, van Laarhoven HW, Bos MM, van de Velde CJ, Gratama JW, Sieuwerts AM, Martens JW, Foekens JA, Sleijfer S.

Mol Cancer Ther. 2015 Mar;14(3):821-7. doi: 10.1158/1535-7163.MCT-14-0653.

14.

Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.

Königsberg R, Obermayr E, Bises G, Pfeiler G, Gneist M, Wrba F, de Santis M, Zeillinger R, Hudec M, Dittrich C.

Acta Oncol. 2011 Jun;50(5):700-10. doi: 10.3109/0284186X.2010.549151.

PMID:
21261508
15.

Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.

Chang DZ, Ma Y, Ji B, Liu Y, Hwu P, Abbruzzese JL, Logsdon C, Wang H.

J Hematol Oncol. 2012 Apr 4;5:15. doi: 10.1186/1756-8722-5-15.

16.

Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients.

Lustberg MB, Balasubramanian P, Miller B, Garcia-Villa A, Deighan C, Wu Y, Carothers S, Berger M, Ramaswamy B, Macrae ER, Wesolowski R, Layman RM, Mrozek E, Pan X, Summers TA, Shapiro CL, Chalmers JJ.

Breast Cancer Res. 2014 Mar 6;16(2):R23. doi: 10.1186/bcr3622.

17.

Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer.

Strati A, Kasimir-Bauer S, Markou A, Parisi C, Lianidou ES.

Breast Cancer Res. 2013 Mar 7;15(2):R20. doi: 10.1186/bcr3395.

18.

Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer.

Guller U, Zajac P, Schnider A, Bösch B, Vorburger S, Zuber M, Spagnoli GC, Oertli D, Maurer R, Metzger U, Harder F, Heberer M, Marti WR.

Ann Surg. 2002 Dec;236(6):768-75; discussion 775-6.

19.

Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.

Li DD, Fu ZQ, Lin Q, Zhou Y, Zhou QB, Li ZH, Tan LP, Chen RF, Liu YM.

World J Gastroenterol. 2015 Aug 21;21(31):9348-57. doi: 10.3748/wjg.v21.i31.9348.

20.

Prognostic value of occult tumor cells obtained by peritoneal lavage in patients with resectable pancreatic cancer and no ascites: A systematic review.

Steen W, Blom R, Busch O, Gerhards M, Besselink M, Dijk F, Festen S.

J Surg Oncol. 2016 Nov;114(6):743-751. doi: 10.1002/jso.24402. Review.

PMID:
27642007
Items per page

Supplemental Content

Support Center